Isabel Marzo

List of Publications by Year
in descending order

101	12,133	57758 44	34986 98
papers	citations	h-index	g-index

105	105	105	12095
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma. Cells, 2022, 11, 392.	4.1	7
2	Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). Scientific Reports, 2022, 12, 1341.	3.3	11
3	Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment. Biomedicines, 2022, 10, 1223.	3.2	2
4	Multifunctional Heterometallic Ir^{III}â^'Au^I Probes as Promising Anticancer and Antiangiogenic Agents. Chemistry - A European Journal, 2021, 27, 9885-9897.	3.3	17
5	Future prospects for mitosis-targeted antitumor therapies. Biochemical Pharmacology, 2021, 190, 114655.	4.4	24
6	Dual Emissive Ir(III) Complexes for Photodynamic Therapy and Bioimaging. Pharmaceutics, 2021, 13, 1382.	4.5	9
7	Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. OncoImmunology, 2021, 10, 1853314.	4.6	24
8	Synthesis of New Thiourea-Metal Complexes with Promising Anticancer Properties. Molecules, 2021, 26, 6891.	3.8	13
9	Novel ureido-dihydropyridine scaffolds as theranostic agents. Bioorganic Chemistry, 2020, 105, 104364.	4.1	5
10	Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Scientific Reports, 2020, 10, 19398.	3.3	23
11	Heterobimetallic propargyl gold complexes with Ï€-bound copper or silver with enhanced anticancer activity. Dalton Transactions, 2020, 49, 11736-11742.	3.3	15
12	Luminescent Bimetallic Ir^{III}/Au^I Peptide Bioconjugates as Potential Theranostic Agents. Chemistry - A European Journal, 2020, 26, 12085-12085.	3.3	1
13	Luminescent Re(I)/Au(I) Species As Selective Anticancer Agents for HeLa Cells. Inorganic Chemistry, 2020, 59, 8960-8970.	4.0	24
14	Novel Forms of Immunomodulation for Cancer Therapy. Trends in Cancer, 2020, 6, 518-532.	7.4	17
15	Luminescent Bimetallic Ir^{III}/Au^I Peptide Bioconjugates as Potential Theranostic Agents. Chemistry - A European Journal, 2020, 26, 12158-12167.	3.3	19
16	Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 50.	3.7	139
17	Bioactive and luminescent indole and isatin based gold(i) derivatives. Dalton Transactions, 2019, 48, 3098-3108.	3.3	17
18	Response: Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 306.	3.7	4

#	Article	IF	Citations
19	Study of the anticancer properties of optically active titanocene oximato compounds. Journal of Organometallic Chemistry, 2019, 881, 150-158.	1.8	5
20	Biological evaluation of water soluble arene Ru(II) enantiomers with amino-oxime ligands. Journal of Inorganic Biochemistry, 2018, 183, 32-42.	3.5	12
21	Bioactive Heterobimetallic Re(I)/Au(I) Complexes Containing Bidentate N-Heterocyclic Carbenes. Organometallics, 2018, 37, 3993-4001.	2.3	27
22	Ylide Ligands as Building Blocks for Bioactive Groupâ€...11 Metal Complexes. Chemistry - A European Journal, 2018, 24, 11693-11702.	3.3	15
23	Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects. Biochemical Pharmacology, 2017, 136, 12-23.	4.4	52
24	Highly active group 11 metal complexes with Î±-hydrazidophosphonate ligands. Dalton Transactions, 2017, 46, 13745-13755.	3.3	13
25	Trackable Metallodrugs Combining Luminescent Re(I) and Bioactive Au(I) Fragments. Inorganic Chemistry, 2017, 56, 15159-15170.	4.0	48
26	Synthesis of luminescent squaramide monoesters: cytotoxicity and cell imaging studies in HeLa cells. RSC Advances, 2016, 6, 14171-14177.	3.6	21
27	High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. Cancer Letters, 2016, 383, 250-260.	7.2	42
28	Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo. Cancer Letters, 2016, 382, 1-10.	7.2	74
29	Cytotoxicity and biodistribution studies of luminescent Au(<scp>i</scp>) and Ag(<scp>i</scp>) N-heterocyclic carbenes. Searching for new biological targets. Dalton Transactions, 2016, 45, 15026-15033.	3.3	58
30	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports, 2015, 13, 2715-2727.	6.4	118
31	Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. Journal of Medicinal Chemistry, 2015, 58, 5825-5841.	6.4	88
32	Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Current Opinion in Pharmacology, 2015, 23, 74-81.	3.5	75
33	Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells. Clinical and Translational Oncology, 2015, 17, 657-667.	2.4	27
34	Human NK cells activated by EBV⁺lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. OncoImmunology, 2015, 4, e991613.	4.6	36
35	Highly Cytotoxic Bioconjugated Gold(I) Complexes with Cysteineâ€Containing Dipeptides. Chemistry - A European Journal, 2015, 21, 11088-11095.	3.3	49
36	Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. Clinical and Translational Oncology, 2015, 17, 121-132.	2.4	21

#	Article	IF	Citations
37	In Vitro and in Vivo Evaluation of Water-Soluble Iminophosphorane Ruthenium(II) Compounds. A Potential Chemotherapeutic Agent for Triple Negative Breast Cancer. Journal of Medicinal Chemistry, 2014, 57, 9995-10012.	6.4	87
38	Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors. Biochemical Pharmacology, 2014, 87, 410-423.	4.4	29
39	Synthesis, Characterization, and Cytotoxic Activity of AuIN,S-Heterocyclic Carbenes Derived from Peptides ContainingL-Thiazolylalanine. European Journal of Inorganic Chemistry, 2014, 2014, 2512-2519.	2.0	35
40	Gold(i) thiolates containing amino acid moieties. Cytotoxicity and structureâ€“activity relationship studies. Dalton Transactions, 2014, 43, 17054-17066.	3.3	33
41	Luminescent Re(<scp>i</scp>) and Re(<scp>i</scp>)/Au(<scp>i</scp>) complexes as cooperative partners in cell imaging and cancer therapy. Chemical Science, 2014, 5, 4434-4446.	7.4	74
42	Antimitotic drugs in cancer chemotherapy: Promises and pitfalls. Biochemical Pharmacology, 2013, 86, 703-710.	4.4	72
43	Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells. Molecular Pharmaceutics, 2013, 10, 893-904.	4.6	70
44	Direct Interaction of Bax and Bak Proteins with Bcl-2 Homology Domain 3 (BH3)-only Proteins in Living Cells Revealed by Fluorescence Complementation. Journal of Biological Chemistry, 2013, 288, 4935-4946.	3.4	74
45	Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199. Blood, 2013, 122, 3919-3919.	1.4	2
46	Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand As Potential Anticancer Agents. Organometallics, 2012, 31, 5772-5781.	2.3	70
47	Cytotoxic hydrophilic iminophosphorane coordination compounds of d8 metals. Studies of their interactions with DNA and HSA. Journal of Inorganic Biochemistry, 2012, 116, 204-214.	3.5	56
48	Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochemical Pharmacology, 2012, 83, 1475-1483.	4.4	45
49	Bortezomib resistance in a myeloma cell line is associated to PSMÎ²5 overexpression and polyploidy. Leukemia Research, 2012, 36, 212-218.	0.8	75
50	Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold. Toxicology and Applied Pharmacology, 2012, 258, 384-393.	2.8	24
51	Iminophosphoraneâ€“organogold(III) complexes induce cell death through mitochondrial ROS production. Journal of Inorganic Biochemistry, 2011, 105, 1306-1313.	3.5	57
52	Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 311-322.	4.1	19
53	Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells. Biochemical Pharmacology, 2010, 79, 1746-1758.	4.4	26
54	Detection ofClostridium tyrobutyricumspores using polyclonal antibodies and flow cytometry. Journal of Applied Microbiology, 2010, 108, 488-498.	3.1	17

#	Article	IF	Citations
55	Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochemical Pharmacology, 2009, 77, 804-812.	4.4	51
56	Bcl-2 family members as molecular targets in cancer therapy. Biochemical Pharmacology, 2008, 76, 939-946.	4.4	75
57	Exposure of any of two proapoptotic domains of presenilin 1-associated protein/mitochondrial carrier homolog 1 on the surface of mitochondria is sufficient for induction of apoptosis in a Bax/Bak-independent manner. European Journal of Cell Biology, 2008, 87, 325-334.	3.6	18
58	Individual Variation of Scavenger Receptor Expression in Human Macrophages with Oxidized Low-Density Lipoprotein Is Associated with a Differential Inflammatory Response. Journal of Immunology, 2007, 179, 3242-3248.	0.8	64
59	Conjugation of a novel Apaf-1 inhibitor to peptide-based cell-membrane transporters:. Peptides, 2007, 28, 958-968.	2.4	31
60	Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss. Molecular Immunology, 2007, 44, 1446-1453.	2.2	18
61	Mechanism of apoptosis induced by IFN-Î± in human myeloma cells: Role of Jak1 and Bim and potentiation by rapamycin. Cellular Signalling, 2007, 19, 844-854.	3.6	38
62	Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Experimental Cell Research, 2007, 313, 2378-2388.	2.6	53
63	Human CD8+ Tâ€„cell blasts are more sensitive than CD4+ Tâ€„cell blasts to regulation by APO2L/TRAIL. European Journal of Immunology, 2005, 35, 1812-1821.	2.9	27
64	Farnesyltransferase Inhibitor BMS-214662 Induces Apoptosis in Myeloma Cells through PUMA Up-Regulation, Bax and Bak Activation, and Mcl-1 Elimination. Molecular Pharmacology, 2005, 67, 1991-1998.	2.3	34
65	Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c- FLIP, Bim, or Bcl-x isoform expression. Journal of Leukocyte Biology, 2005, 77, 568-578.	3.3	37
66	Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-Î± in human myeloma cells. FEBS Letters, 2005, 579, 6217-6222.	2.8	20
67	Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia, 2004, 18, 1599-1604.	7.2	17
68	Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia. Leukemia, 2002, 16, 2106-2114.	7.2	36
69	Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochemical Journal, 2001, 359, 537-546.	3.7	83
70	A Role of the Mitochondrial Apoptosis-Inducing Factor in Granulysin-Induced Apoptosis. Journal of Immunology, 2001, 167, 1222-1229.	0.8	103
71	Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochemical Journal, 2001, 359, 537.	3.7	52
72	Purification and Liposomal Reconstitution of Permeability Transition Pore Complex. Methods in Enzymology, 2000, 322, 243-252.	1.0	15

#	Article	IF	Citations
73	Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene, 2000, 19, 329-336.	5.9	322
74	Mitochondrial Release of Caspase-2 and -9 during the Apoptotic Process. Journal of Experimental Medicine, 1999, 189, 381-394.	8.5	678
75	Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 1999, 397, 441-446.	27.8	3,697
76	Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene, 1999, 18, 2537-2546.	5.9	194
77	Arsenite Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore. Experimental Cell Research, 1999, 249, 413-421.	2.6	283
78	Mitochondrial permeability transition in apoptosis and necrosis. Cell Biology and Toxicology, 1998, 14, 141-145.	5.3	121
79	The thiol crosslinking agent diamide overcomes the apoptosis-inhibitory effect of Bcl-2 by enforcing mitochondrial permeability transition. Oncogene, 1998, 16, 1055-1063.	5.9	149
80	Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene, 1998, 16, 2265-2282.	5.9	385
81	Editorial. Experimental Gerontology, 1998, 33, 543-553.	2.8	25
82	Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunology Letters, 1998, 61, 157-163.	2.5	195
83	La mitochondrie, chef d'orchestre de la mort cellulaire. Biofutur, 1998, 1998, 32-36.	0.0	0
84	Bax and Adenine Nucleotide Translocator Cooperate in the Mitochondrial Control of Apoptosis. , 1998, 281, 2027-2031.		1,061
85	Loss of Î´6-desaturase activity leads to impaired docosahexaenoic acid synthesis in Y-79 retinoblastoma cells. Prostaglandins Leukotrienes and Essential Fatty Acids, 1998, 59, 293-297.	2.2	8
86	The central role of the mitochondrial megachannel in apoptosis: evidence obtained with intact cells, isolated mitochondria, and purified protein complexes. Biomedicine and Pharmacotherapy, 1998, 52, 248-251.	5.6	74
87	Caspases disrupt mitochondrial membrane barrier function. FEBS Letters, 1998, 427, 198-202.	2.8	123
88	The Permeability Transition Pore Complex: A Target for Apoptosis Regulation by Caspases and Bcl-2â€“related Proteins. Journal of Experimental Medicine, 1998, 187, 1261-1271.	8.5	657
89	CoopÃ©ration mortelle entre la protÃ©ine pro-apoptotique Bax et le translocateur Ã adÃ©nine nuclÃ©otide pour le contrÃ1e mitochondrial de l'apoptose.. Medecine/Sciences, 1998, 14, 1399.	0.2	0
90	A Cytofluorometric Assay of Nuclear Apoptosis Induced in a Cell-Free System: Application to Ceramide-Induced Apoptosis. Experimental Cell Research, 1997, 236, 397-403.	2.6	73

#	Article	IF	Citations
91	Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. FEBS Letters, 1997, 410, 373-377.	2.8	220
92	The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene, 1997, 15, 1573-1581.	5.9	443
93	Role of the Mitochondrial Permeability Transition Pore in Apoptosis. Bioscience Reports, 1997, 17, 67-76.	2.4	193
94	Glutathione depletion is an early and calcium elevation is a late event of thymocyte apoptosis. Journal of Immunology, 1997, 158, 4612-9.	0.8	205
95	CPP32 inhibition prevents Fas-induced ceramide generation and apoptosis in human cells. FEBS Letters, 1996, 390, 233-237.	2.8	78
96	Biosynthesis of docosahexaenoic acid in human cells: evidence that two different Î”6-desaturase activities may exist. Lipids and Lipid Metabolism, 1996, 1301, 263-272.	2.6	47
97	Biosynthesis of unsaturated fatty acids in the main cell lineages of human leukemia and lymphoma. Lipids and Lipid Metabolism, 1995, 1257, 140-148.	2.6	33
98	mtDNA-depleted U937 cells are sensitive to TNF and Fas-mediated cytototxicity. FEBS Letters, 1995, 376, 15-18.	2.8	32
99	Self-Staining of Polyunsaturated Fatty Acids in Argentation Thin-Layer Chromatography. Analytical Biochemistry, 1994, 220, 210-212.	2.4	17
100	Alternative route for the biosynthesis of polyunsaturated fatty acids in K562 cells. Biochemical Journal, 1993, 291, 841-845.	3.7	25
101	Synthesis and antiproliferative study of phosphorescent multimetallic Re(I)/Au(I) complexes containing fused imidazo[4,5â€f]â€1,10â€phenanthroline core. Applied Organometallic Chemistry, 0, , .	3.5	4